TrialPath

Find a study

Match me to a study

857 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

147 studies on the map

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleStudy of ALTO-300 in MDD — Site 200, PhoenixZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamHome Based Functional Balance Intervention for Multiple Sclerosis — University of Illinois at Chicago, ChicagoDry Needling in Multiple Sclerosis — University of South Florida, TampaA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — Anaheim Clinical Trials, AnaheimA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertTreatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) — University of Alabama at Birmingham - Dept. of Psychiatry, BirminghamSequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation — Mayo Clinic in Rochester, RochesterA Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — TG Therapeutics Investigational Trial Site, BirminghamBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, Huntsville"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamA Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome — Clinical Research Institute of Arizona, Sun City WestEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoUblituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoA Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis — Kessler Foundation, East HanoverA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideExamining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors — Fort Carson, Colorado SpringsA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenReducing Fatigue in People With Multiple Sclerosis by Treatment With TENS — University of Colorado, Boulder"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS — University of California, San Francisco, San FranciscoStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease — Knowledge Research Center, OrangePhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockEffect of Cooling on Balance Performance in Multiple Sclerosis — Hunter College, Physical Therapy Department, City University of New York, New YorkClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoHyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis — Byers Hall, San FranciscoNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleTreatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation — The University of Texas at Dallas, RichardsonA Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamEvaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain — Shirley Ryan AbilityLab, ChicagoThe SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study — Shepherd Center, AtlantaCare in Multiple Sclerosis (MS) — University of Alabama at Birmingham, BirminghamConfirmatory Trial for Alleviating Fatigue in Multiple Sclerosis — Washington VA Medical Center, Washington D.C.A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadPredictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) — Northwestern University, ChicagoThe OBSERVE Protocol — Mood Institute, MilfordPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordA Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — PROVIDE Virtual Research Coordination Center, San FranciscoMood and Thought Process Study — Butler Hospital, ProvidenceTriage Survey for Psychiatry Research Eligibility — Adams Clinical, Boston, BostonA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoCBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms — Intrepid Spirit Center - Eglin Air Force Base, Eglin Air Force BaseGenes and Environment in Multiple Sclerosis — National Institute of Neurological Disorders and Stroke, BethesdaSleep and Circadian Interventions for College Students at High Risk of Suicide — Western Psychiatric Hospital/University of Pittsburgh, PittsburghUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonType I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans — Phoenix VA Health Care System, Phoenix, AZ, PhoenixImproving Behavioral Health for Caregivers and Children After Pediatric Injury — Children's Hospital Los Angeles, Los AngelesSAINT in Postpartum Depression (PPD) — UMass Chan Medical School, WorcesterE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixLay-Delivered Behavioral Activation in Senior Centers — Brandon Senior Center, BrandonStudy on Allopregnanolone and Depression in Women Across the Menopause Transition — Beth Israel Deaconess Medical Center, BostonCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookDeep Brain Stimulation of Treatment-Resistant Bipolar Depression — Massachusetts General Hospital, BostonENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiBTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women — Charak Center for Health & Wellness, Garfield HeightsCharacterization and Treatment of Adolescent Depression — University of Southern California, Los AngelesPositive Processes and Transition to Health (PATH) — University of Delaware, NewarkWellness App for Sleep Disturbance in Hematological Cancer Patients — Arizona State University, PhoenixFamily Spirit Strengths — Johns Hopkins Center for Indigenous Health, ChinlerTMS for Military TBI-related Depression — VA Palo Alto Health Care System, Palo AltoAssessing Improvements in Mood and Sleep Trial — The Regents of the University of California, Los Angeles, Los AngelesProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraCentral Vein Sign in Multiple Sclerosis Extension Study — Cedars-Sinai Medical Center, Los AngelesClinical Trial for Integrated Care to Help At Risk Teen (iCHART) Intervention — Gibbsboro, GibbsboroStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaComputer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics — Connecticut Mental Health Center, HamdenPregnancy Exposure Registry for Vumerity (Diroximel Fumarate) — University of Colorado Anschutz Medical Campus, AuroraEffectiveness, Implementation, and Cost of Cognitive Processing Therapy in Prisons — University of Arkansas for Medical Sciences, Little RockStudy to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis — Minneapolis Clinic of Neurology, Golden ValleyBrain Connectivity in Depression — Brigham and Women's Hospital, BostonHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis — Children's Hospital Los Angeles, Los AngelesRIVER At Home Ketamine Protocols — RIVER Foundation, BigforkMilitary Health and Nutrition Examination Study — Fort Campbell, Fort CampbellMechanisms of Rumination Change in Adolescent Depression — Nationwide Children's Hospital, ColumbusTranscranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33 — Harvard Medical School, BostonSelf Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia — Butler Hospital, ProvidenceModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraImplementing Depression and Adherence Treatment — University of Miami, MiamiSilverCloud as a School-Based Intervention for Vulnerable Youth — Rutgers University, New BrunswickMaintenance rTMS for Depression (Maitr-De) — University of California, San Diego, San DiegoBTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women — Luxury Psychiatry Clinic, Winter GardenSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoIMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy — Hospital for Special Surgery, New YorkMultiple Sclerosis Implementation Network (Registry) — Multiple Sclerosis Association of America, Cherry HillEnhancing Brain And Mental Health Through Breathing Practice — Mayo Clinic Health System-Albert Lea, Albert LeaAssessment of Music Experiences in Navigating Depression Part 2 — Mount Sinai Union Square, New YorkResearching Heat and Yoga for Mood Enhancement — Orange Door Collaborative, CambridgeDigital InteGrated Behavioral TreatmeNt for Comorbid ObesITy and DeprEssion Among Racial and Ethnic Adults Age 50 and Older — Department of Medicine, Vitoux Program on Aging and Prevention, ChicagoBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordNeural and Psychiatric Consequences of Cannabis Use in Adolescents — University of Miami Clinical Research Building, MiamiCharacterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project — University of California, San Francisco, San FranciscoPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoComparing Cognitive-Behavioral Therapy Versus Mindfulness-Based Therapy for Autistic Adults — University of North Carolina at Chapel Hill, Chapel HillPupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy — UCSF Benioff Children's Hospital, San FranciscoCombining rTMS & Aerobic Exercise to Treat Depression and Improve Post-Stroke Walking — Duke University School of Medicine, DurhamMindfulness-Based fMRI Neurofeedback for Depression — Northeastern University, BostonSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleTeenthrive 2: Treatments for Improving Mood in Teens — Beth Israel Deaconess Medical Center, BostonStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixBrain Stimulation for Severe Depression — Massachusetts General Hospital, BostonRESISTance Exercise for Depression Trial — Iowa State University, AmesTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreHigh-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis — Rehabilitation Hospital of Indiana, IndianapolisTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityMental Health in Primary Care — Jessie Trice Community Health Center, MiamiPilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS) — Carolina Center for Neurostimulation, Chapel HillObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityEnhancing Engagement by Integrating Goals and Concerns That Matter to Patients — Dartmouth Hitchcock Concord Family Medicine, Concord

Showing the 150 nearest — narrow your filters for fewer, closer studies.